Methods for diagnosing celiac sprue and reagents useful therein

Details Methods for diagnosing celiac sprue and reagents useful therein Methods for diagnosing celiac sprue and reagents useful therein

2011-04-12

2011-04-12

Audet, Maury (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

11 to 14 amino acid residues in defined sequence

C424S001690, C514S001100, C435S006120

Reexamination Certificate

active

07923532

ABSTRACT:
Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

REFERENCES:
patent: 4203967 (1980-05-01), Gallo-Torres
patent: 4912120 (1990-03-01), Castelhano et al.
patent: 4929630 (1990-05-01), Castelhano et al.
patent: 5817523 (1998-10-01), Picarelli
patent: 5834428 (1998-11-01), Drucker
patent: 6197356 (2001-03-01), Girsh
patent: 6294320 (2001-09-01), Hruska et al.
patent: 6319726 (2001-11-01), Schuppan et al.
patent: 6410550 (2002-06-01), Coe et al.
patent: 6962989 (2005-11-01), Pompejus et al.
patent: 7144569 (2006-12-01), Anderson et al.
patent: 7202216 (2007-04-01), Sollid et al.
patent: 7462688 (2008-12-01), Khosla et al.
patent: 2001/0007690 (2001-07-01), Girsh
patent: 2001/0036639 (2001-11-01), Fine
patent: 2002/0039599 (2002-04-01), Lin et al.
patent: 2002/0076834 (2002-06-01), Detlef et al.
patent: 2003/0215438 (2003-11-01), Hausch et al.
patent: 2003/0224476 (2003-12-01), Chou
patent: 2004/0167069 (2004-08-01), Khosla et al.
patent: 2004/0241664 (2004-12-01), Dekker et al.
patent: 2005/0090653 (2005-04-01), Klaveness et al.
patent: 2005/0244823 (2005-11-01), Drijfhout et al.
patent: 2006/0052308 (2006-03-01), Khosla et al.
patent: 2006/0178299 (2006-08-01), Anderson et al.
patent: 2006/0240475 (2006-10-01), Khosla et al.
patent: 2008/0299108 (2008-12-01), Khosla et al.
patent: 2009/0156490 (2009-06-01), Khosla et al.
patent: 2009/0304754 (2009-12-01), Robic
patent: 0237082 (1987-09-01), None
patent: 0 905 518 (1999-03-01), None
patent: WO 94/26774 (1994-11-01), None
patent: 96/10034 (1996-04-01), None
patent: 00/42213 (2000-07-01), None
patent: 01/25793 (2001-04-01), None
patent: WO 01/25793 (2001-04-01), None
patent: 01/25793 (2001-12-01), None
patent: 03068170 (2003-08-01), None
patent: 03/096984 (2003-11-01), None
patent: 2004/045392 (2004-06-01), None
patent: 2005/049064 (2005-06-01), None
Neagele et al. (Zeitschrift fuer Lebensmittel-Untersuchung und—Forschung (1991), 192(5), 415-21).
Auger; et al., “Solid-State 13C NMR Study of a Transglutaminase-Inhibitor Adduct”, Biochemistry (1993), 32:3930-3934.
Cornell; et al., “In vitro mucosal digestion of synthetic gliadin-derived peptides in celiac disease”, Journal of Protein Chemistry (1995), 14(5):335-339.
Goldsmith; et al., “Inhibition of Human Epidermal Transglutaminases In-Vitro and In-Vivo by Tyrosineamidomethyldihydrohaloisoxazoles”, Journal of Investigative Dermatology (1991), 97(1):156-158.
Killackey; et al., “A New Class of Mechanism-Based Inhibitors of Translutaminase Enzymes Inhibits the Formation of Cross-Linked Envelopes by Human Malignant Keratinocytes”, Molecular Pharmacology (1989), 35(5):701-706.
Piper; et al., “Effect of Prolyl Endopeptidase on Digestive-Resistant Gliadin Peptides in Vivo”, Journal of Pharmacology and Experimental Therapeutics (2004), 311(1):213-219.
Shan; et al., “Comparative biochemical analysis of three bacterial prolyl endopeptidases: Implications for coeliac sprue”, Biochemical Journal (2004), 382(2):311-318.
Watts; et al., “Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles”, Journal of Medicinal Chemistry (2006), 49(25):7493-7501.
Qiao; et al., “Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion”, Journal of Immunology (2004), 173(3):1757-1762.
Xia; et al., Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2, Biochemistry (2005), 44(11):4442-4449.
Smith; et al., “Abnormal expression of dipeptidylpeptidase IV activity in enterocyte brush-border membranes of children suffering from coeliac disease”, Experimental Physiology, Jul. 1990, 74(4):613-616.
Wruble, Milton, “Enteric Coating. I. A Laboratory Method for the Study and Control of Enteric Coatings”, Journal of the American Pharmaceutical Association, Jul. 1935, XXIV(7):570-574.
Arentz-Hansen et al. “Celiac Lesion T Cells Recognizes Epitopes that Cluster in Regions of Gliadins Rich in Proline Residues” Gastroenterology, 2002, pp. 803-809, vol. 123, No. 3.
Castelhano et al., “Synthesis, Chemistry, and Absolute Configuratin of Novel Transglutaminiase Inhibitors Containing a 3-Halo-4,5-dihydroisoxazole” Bioorg. Chem., 1988, pp. 335-340, vol. 16.
Choi et al. “Chemistry and Biology of Dihydroisoxazole Derivatives: Selectives Inhibitors of Human transglutaminase 2” Chem. & Biol., 2005, pp. 469-475, vol. 12.
Colot et al. “The Genes Encoding Wheat Storage Proteins: Towards A Molecular Understanding Of Bread-Making Quality and Its Genetic Manipulation” Genet Eng, 1990, pp. 225-241, vol. 12.
de Ritis G. et al. “In Vitro (organ culture) Studies of the Toxicity of Specific A-Gliadin Peptides in celiac Disease” Gastroenbterology, 1988, pp. 41-49, vol. 94.
Frazer et al. “Gluten-induced enteropathy: the effect of partially digested gluten.” Lancet, Sep. 5, 1959, pp. 252-255, vol. 2.
Freund, K. et al., “Transglutaminase inhibition by 2-[(2-Oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation” Biochemistry, 1994, pp. 10109-10119, vol. 33.
Greenberg, C. et al. “Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues” FASEB J., 1991, pp. 3071-3077, vol. 5.
Hausch et al. “Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase” Chem Biol., Mar. 2003, pp. 225-231, vol. 10, Issue 3.
Hitomi, K. et al. “GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3),” Biosci. Biotechnol. Biochem., 2000, pp. 657-659, vol. 64, Issue 3.
Karpuj et al. “Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with adminstration of the transglutaminase inhibitor cystamine” Nature Med., Feb. 2002, pp. 143-149, vol. 8, Issue 2.
Keillor, J. “Tissue Transglutaminase Inhibition” Chem. & Biol., 2005, pp. 410-412, vol. 12.
Kim et al. “Transglutaminases in disease” Neurochem. Int., 2002, pp. 85-103, vol. 40.
Lorand et al. “Novel inhibitors against the transglutaminase-catalysed crosslinking of lens proteins” Exp Eye Res., May 1998, pp. 531-536, vol. 66.
Martinet et al. “In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer” Am J Respir Cell Mol Biol., Apr. 2003, pp. 428-435, vol. 28, Issue 4.
Messer et al. “Studies On The Mechanism Of Destruction Of The Toxic Action Of Wheat Gluten In Coeliac Disease By Crude Papain” Gut., Aug. 1964, pp. 295-303, vol. 5.
Messer et al.“Oral papain in gluten intolerance.” Lancet, Nov. 6, 1976, p. 1022, vol. 2, Issue 7993.
Moodie, P. “Traditional Baking Enzymes-Proteases” Presented at the American Institute of Baking, Manhattan, Kansas, May 7, 2001 by Peter Moodie, Director—Sales & Marketing, Enzyme Development Corporation, Enzyme Development Corporation.
Online-Medical Dictionary. “Amino acid”. http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=amino+acid. Nov. 13, 1997.
Piper et al., “High selectivity of human tissue transglutaminase for immunoactive gliadin peptides: implications for celiac spure”, Biochemistry, Jan. 8, 2002, pp. 386-393, vol. 41, Issue 1.
Sárdy, M. et al., “Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis” J. Exp. Med., 2002, pp. 747-757, vol. 195, Issue 6.
Shan, L. et al. “Structural Basis for Gluten Intolerance in Celiac Sprue” Science 2002, pp. 2275-2279, vol. 297.
Sjostrom et al. &#x

Affiliated with

Also associated with

Rating

Methods for diagnosing celiac sprue and reagents useful therein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosing celiac sprue and reagents useful therein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing celiac sprue and reagents useful therein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2652985